GCN2 deficiency protects mice from denervation-induced skeletal muscle atrophy via inhibiting FoxO3a nuclear translocation

Yuting Guo, Huiwen Wang, Yinglong Tang, Yue Wang, Mengqi Zhang, Zhiguang Yang, Eric Nyirimigabo, Bin Wei, Zhongbing Lu, Guangju JiProtein 2018 · DOI · OpenAlex

Introduction

Skeletal muscle atrophy—the loss of muscle mass and strength—is a debilitating consequence of aging, malnutrition, and nerve damage (denervation). While clinical studies show that branched-chain amino acids (BCAAs) like leucine can help slow this process, the underlying molecular "sensor" that translates nutrient status into muscle preservation or degradation has remained elusive. This study identifies GCN2 (General control nonderepressible 2 kinase), a well-known sensor of amino acid deficiency, as a critical mediator of muscle wasting following nerve injury.

Methods

The study employed a combination of in vivo mouse models and in vitro cell culture techniques to investigate the role of GCN2:

  • Genetic Models: Researchers compared wild-type (WT) mice to GCN2-deficient ($Gcn2^{-/-}$) mice.
  • Denervation Model: Sciatic nerve denervation was used to induce atrophy in hindlimb muscles, including the Tibialis Anterior (TA), Gastrocnemius (GAS), and Extensor Digitorum Longus (EDL).
  • Histology: Wheat germ agglutinin (WGA) staining was used to measure myofiber cross-sectional area (CSA) and distribution.
  • Gain-of-Function: To confirm GCN2's role, the team overexpressed GCN2 in the Flexor Digitorum Brevis (FDB) muscle using in vivo electroporation.
  • Molecular Signaling: Western blotting, immunostaining, and Co-immunoprecipitation (Co-IP) were used to track the physical interaction and nuclear translocation of FoxO3a.

Key Insights

  • GCN2 as an Atrophy Driver: Rather than just a passive sensor, GCN2 acts as a necessary mediator for muscle wasting. Without it, the muscle is significantly more resilient to the effects of nerve loss.
  • The FoxO3a Connection: GCN2 deficiency prevents FoxO3a from entering the nucleus. In healthy muscle, FoxO3a stays in the cytoplasm; during atrophy, it moves to the nucleus to activate "atrogenes" (like Atrogin-1 and MuRF-1) that trigger protein degradation. GCN2 appears to be the gatekeeper for this translocation.
  • Physical Interaction: Co-IP experiments revealed that GCN2 and FoxO3a physically interact within the cell, suggesting GCN2 may directly regulate FoxO3a through phosphorylation or by acting as a scaffold.

Key Results

The experimental data demonstrates that GCN2 deficiency significantly blunts the effects of denervation on muscle mass and fiber size.

GCN2 deficiency attenuates denervation-induced muscle atrophy and fiber size reduction. Panel A shows muscle weight preservation; Panels B and C show fiber cross-sectional area (CSA) and distribution; Panel D shows the effect of GCN2 overexpression.
  • Muscle Mass Preservation: Seven days after denervation, WT Tibialis Anterior (TA) muscle mass dropped to 70.9% of its original weight. In contrast, GCN2-deficient TA muscles maintained 83.1% of their mass.
  • Fiber Size Distribution: In WT mice, denervation caused a dramatic "leftward shift" in fiber size distribution (meaning fibers got much smaller). This shift was significantly blunted in the $Gcn2^{-/-}$ mice.
  • Atrogene Suppression: GCN2-deficient muscles showed significantly lower levels of E3 ubiquitin ligases (Atrogin-1 and MuRF-1) and a lower ratio of LC3-II/I (a marker of autophagy) compared to WT atrophic muscles.
  • Dose-Response Effect: Overexpressing GCN2 in already atrophying muscle made the wasting significantly worse, confirming a direct correlation between GCN2 levels and the severity of muscle loss.

Discussion and Future Directions

While this study proves GCN2 is required for FoxO3a nuclear translocation, the exact biochemical mechanism (e.g., which specific residues GCN2 might phosphorylate on FoxO3a) remains to be fully mapped. Additionally, while GCN2 deficiency is protective in denervation models, it is currently unknown if it would be equally protective in other models of atrophy, such as cancer cachexia or age-related sarcopenia. Future work must determine if pharmacological inhibition of GCN2 can be targeted specifically to muscle to avoid systemic side effects, given GCN2's vital roles in general cellular homeostasis.

Summary updated

BibTeX
@inproceedings{guo2018gcn,
  author = {Yuting Guo and Huiwen Wang and Yinglong Tang and Yue Wang and Mengqi Zhang and Zhiguang Yang and Eric Nyirimigabo and Bin Wei and Zhongbing Lu and Guangju Ji},
  title = {{GCN2 deficiency protects mice from denervation-induced skeletal muscle atrophy via inhibiting FoxO3a nuclear translocation}},
  booktitle = {Protein},
  year = {2018},
  doi = {10.1007/s13238-018-0504-0},
}
Figure